B7 - Disorders of homeostasis Flashcards

1
Q

What causes bleeding

A
  • Abnormalities of vasculature
    ○ E.g. structural, connective tissue disorders
    ○ Surgeons have to close the vessels properly
    • Defects of primary haemostasis - platelet disorders
    • Defects of secondary haemostasis
      ○ Procoagulant protein deficiency
    • Accelerated breakdown of clot
      ○ hyperfibrinolysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Common causes of thrombocytopaenia

A

○ Impaired bone marrow function
§ Myelodysplasia
§ Leukaemia
§ Bone marrow infiltration
○ Hypersplenism (sequestration) (e.g. chronic liver disease)
○ Acts as a storage site for platelets
○ Increased platelet destruction
§ Severe sepsis/DIC
§ TTP/HUS syndrome
§ Immune thrombocytopaenic purpura (ITP)
§ Autoimmune conditions (SLE, antiphospholipid syndrome)
§ Viral infections (HIV, EBV, hepatitis C, H. pylori)
§ Pre-eclampsia
○ Drug-induced (heparin, gold, quinine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Immune (Idiopathic) thrombocytopaenic purpura (ITP)

A
  • Isolated thrombocytopaenia (remainder of blood count and coagulation testing normal). Diagnosis of exclusion - no gold standard diagnostic test
    • Present with petechiae, epistaxis, bleeding gums
    • Pathogenesis
      ○ Increased platelet destruction - antibody effect
      ○ Inhibition of megakaryocyte platelet production via the production of specific IgG autoantibodies by the patients B cells
    • Presentation
      ○ Children usually present with sudden severe thrombocytopaenia a few weeks after viral infection
      § Usually clears on it’s own
      ○ Adults often present with more gradual onset and more gradual recovery, many do not fully resolve
      ○ Treatment options include steroids, intravenous immunoglobulin (IV Ig), splenectomy, rituximab, TPOmimetics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Platelet function in haemostasis

A
  • Circulating platelets bind to sub-endothelial matrix through platelet surface receptors
    ○ Glycoprotein 1b/IX/V complex via non-Willebrand factor (VWF)
    ○ GPVI binding collagen
    ○ GP1a/IIa
    • Platelets are activated by collagen, thrombin
    • Activated platelets
      ○ Change shape
      ○ Release their granules (which contain substances such as ADP, TXA2, fibrinogen, VWF)
      ○ Express glycoprotein IIb/IIIa (fibrinogen receptor) - on the surface in a functional form
    • ADP and TXA2 recruit other platelets to help from a platelet plug
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Abnormal Platelet Function

A
  • Congenital
    ○ GP Ib IX-V defect (Bernard-Soulier Syndrome)
    ○ GP IIb/IIIa defect (Glanzmann’s thrombasthaenia)
    • Acquired - usually caused by drugs
      ○ Aspirin - irreversibly inhibits enzyme
      ○ Clopidogrel - inhibits ADP receptor
      ○ Dipyridamole
      ○ Non-steroidal anti-inflammatories
      ○ Uraemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Bleeding disorders and secondary haemostasis

A
- Inherited 
		○ Haemophilia 
		○ Von-Willebrand disease
	- Acquired 
		○ Liver disease 
		○ Vitamin K deficiency 
		○ Renal disease 
		○ Warfarin 
		○ DIC
		○ Massive transfusion
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Congenital deficiency of clotting factor

A
  • Congenital deficiencies described for all except tissue factor
    • Factor XII deficiency not associated with bleeding
      ○ All others are
    • Bleeding potentially due to
      ○ Quantitative defect
      ○ Qualitative defect
      ○ Combined
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Haemophilia

A
  • Rare
    • Severe bleeding
      ○ Diagnosed as infants
      ○ Spontaneous haemarthrosis, muscle haematoma, intracranial haemorrhage, internal bleeding
    • Types
      ○ Haemophilia A: FVIII deficiency
      ○ Haemophilia B: FIX deficiency (Christmas disease)
    • Haemophilia A and B of comparable severity, bleed with similar frequency
    • Inheritance is X linked recessive: predominantly effects males, females are usually carriers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Haemophilia A

A

FVIII deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Haemophilia B

A

FIX deficiency (Christmas disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnosis of haemophilia/bleeding disorders

A
  • Most important screening test is clinical history
    ○ Personal bleeding history
    ○ Drugs
    ○ Family history
    • Laboritory screening test
      ○ Activated partial thromboplastin time (APTT) (prolonged)
      ○ Normal PT, platelet count and fibrinogen
    • Severe is FIX or FVIII level of <1%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Haemophilia Management

A
  • Recombinant (manufactured) FVIII (or IX) replacement for procedures or treatment of bleeds (levels increased from 1% to 50%-100)
    • For people with severe disease - prophylaxis (routine FVIII (or IX) replacement 2-3 times per week) for newly diagnosed children
      ○ Eg. Constantly bleeding into knee may cause arthritis etc.
    • In the 1980’s-90’s haemophiliacs given FVIII from blood donors - group of men with medically-acquired hepatitis C and HIV. ALL current patients in Australia given recombinant product
    • All patients should carry a card detailing the diagnosis, severity and usual treatment
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

bleeding caused by platelet defects

A

mucocutaneous bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

bleeding caused by clotting factor defects

A

deep tissue bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Von-Willebrand Disease VWD

A
  • Most common inherited bleeding disorder
    • Von-Willebrand Protein
      ○ Role in primary haemostasis
      ○ Carrier protein for FVIII
    • Autosomal dominant, 1% population
      ○ Equal males/females
      ○ May be family history of bleeding
    • May have mild bleeding tendency
      ○ Epistaxis, mucosal bleeding, menorrhagia, easy bruising
      ○ Many are diagnosed after haemorrhage following tooth extraction or tonsillectomy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

types of von willebrand disease

A

○ Type 1 - decreased quantity of VWF - mild
○ Type 2 - decreased function of VWF
○ Type 3 - rare, sever deficiency of VWF due to inheriting two mutated genes (one from each parent) presents as haemophilia with similar style bleeding to a severe case

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

von willebrand disease diagnosis

A

○ May or may not have a prolonged APTT (VWF carrier protein for FVIII)
○ Specific tests to diagnose ‘von-Willebrand screen’
§ VWF antigen
§ VWF function (collagen binding, ristocetin cofactor)
§ Factor VIII levels (VWF carrier protein for FVIII)
○ Normal >50%, abnormal <30%, 30-50%?

18
Q

von willebrand disease management

A

○ Depend on severity of bleeding
○ DDAVP (desmopressin)
§ IV infusion that increases release of VWF from storage granules in platelets and endothelium
§ Duration of effect 4-6 hours max so must be given on the same day as the procedure
§ Burst of VWF into circulation
§ Good for simple surgeries eg. Tooth extraction
○ Tranexamic acid tablets (or mouthwash)
§ Stabilise fibrin clot, may be taken for the first 4-5 days after procedure
○ Biostate
§ For severe deficiency (type 3) or non-responders to DDAVP plasma-derived product prepared from blood donors that contains FVIII and VWF
§ Needs to be given on the same day as the procedure
§ Or for major surgeries or severe bleeding disorders

19
Q

○ DDAVP (desmopressin)

A

§ IV infusion that increases release of VWF from storage granules in platelets and endothelium
§ Duration of effect 4-6 hours max so must be given on the same day as the procedure
§ Burst of VWF into circulation
§ Good for simple surgeries eg. Tooth extraction

20
Q

○ Biostate

A

§ For severe deficiency (type 3) or non-responders to DDAVP plasma-derived product prepared from blood donors that contains FVIII and VWF
§ Needs to be given on the same day as the procedure
§ Or for major surgeries or severe bleeding disorders

21
Q

○ Vit K deficiency

A

§ Essential for activity of several carboxylase enzymes within hepatic cells, necessary for activation of factors II, VII, IX, X
§ Vit K1 - dietary (green leafy vegies)
§ Vit K2 - synthesised by gut flora
§ Deficiency
1. Neonatal ‘haemorrhagic disease of the newborn’ all neonates are vit K deficient: IM vitamin K at birth - public health scheme to prevent haemorrhagic disease of the newborn
2. Adults
a) Any cause of malnutrition, malabsorbtion (coeliac disease, inflammatory bowel, short bowel, cystic fibrosis etc.)
§ Laboritory diagnosis
□ Prolonged PT
□ Normal fibrinogen and normal/prolonged APTT (because of factors 2 ad 10)

22
Q

Neonatal ‘haemorrhagic disease of the newborn

A

all neonates are vit K deficient: IM vitamin K at birth - public health scheme to prevent haemorrhagic disease of the newborn

23
Q

vit K deficiency lab diagnosis

A

□ Prolonged PT

□ Normal fibrinogen and normal/prolonged APTT (because of factors 2 ad 10)

24
Q

Massive transfusion

A
  • Defined as replacement by transfusion of >50% of blood volume in 12-24 hours
    • In adult usually >10 units of packed cells
    • Dilution of clotting factors, platelets
    • Lab tests: prolonged INR, prolonged APTT, low fibrinogen, low platelets
    • Coagulopathy potentiated by acidosis, hypothermia
    • Many institutions now have massive transfusion protocol e.g. after 4 units packed cells, give 1 unit FFP
25
Q

Disseminated Intravascular Coagulation (DIC)

A
  • Systemic process where the blood is exposed to procoagulant factor (e.g. tissue factor)
    Massive thrombin generation, widespread coagulation, followed by fibrinolysis and depletion of clotting factors
26
Q

DIC causes

A
- Causes 
		○ Acute 
			§ Sepsis 
			§ Severe trauma 
			§ Complications of pregnancy (amniotic fluid embolism, placental abruption, fetal death in utero)
			§ Snake bite 
			§ Acute leukaemia (particularly promyelocytic)
		○ Chronic (compensated)
			§ Cancer
27
Q

DIC clinical presentation

A

○ Bleeding (64%), including spontaneous bleeding from cannula sites
○ Renal dysfunction (25%)
○ Hepatic dysfunction (19%)
○ Respiratory dysfunction (16%)
○ Shock (14%)
○ Thromboembolism (7%)
○ Central nervous system involvement (2%)

28
Q

thrombosis

A
  • Too little breakdown, too much clot formation
    • Risk factors - Virchow’s Triad
      ○ Endothelial injury
      ○ Abnormal blood flow
      ○ Hypercoagulability (too many clotting proteins, to thicker blood flow)
    • Clinical features of deep vein thrombosis
      ○ Usually in leg
      ○ Usually red swollen and painful
29
Q

diagnosis of Deep vein thrombosis

A

○ Presentations to ED with suspected DVT: 20% have DVT and 80% have other cause
○ DVT cannot be safely diagnosed or excluded on history/exam alone
○ Diagnosis involves
§ Assessment of pre-test probablity of DVT - clinical prediction guide
□ D dimer - measures broken down fragments of cross linked fibrin from a clot
® Any reason for having activated thrombosis will increase D dimer measurement
® If your D dimer is normal, DVT can be excluded
® If D dimer is high it is not necessarily DVT
□ Ultasonography USS

30
Q

thrombosis risk factors

A

○ Endothelial injury
○ Abnormal blood flow
○ Hypercoagulability (too many clotting proteins, to thicker blood flow)

31
Q

fibrinolysis

A
  • At the time that the clot is broken down all the fibrin strands are cross linked
    • Cross linked fragments of broken down blood clot are measured with d dimer
32
Q

d-dimer

A
  • Plasmin breaks down cross-linked fibrin to d-dimers (product of fibrinolysis)
    • Occur after a thrombin has formed
    • Found in VTE and post-operatively, DIC, infection, malignancy, trauma
    • Not specific and cannot be used to confirm a diagnosis of DVT
      Why measure D-dimer
    • High negative predictive value, low positive predictive value
33
Q

Clinical features of Pulmonary Embolism (PE)

A
  • Chest pain, shortness of breath, cough, palpitations, syncope, differential diagnosis
    ○ Chest infection
    ○ Cardiac failure
    ○ Malignancy
34
Q

Natural history of Venous thromboembolism

A
  • Usually starts in the calf veins
    • Majority is symptomatic DVT are proximal
    • Pulmonary embolism (PE) usually arise from proximal DVT - some of the clot breaks of and travels to cause a PE
    • ~ 50% of untreated symptomatic proximal DVT are expected to cause symptomatic PE
    • ~10% of symptomatic PE are rapidly fatal
    • ~30% of untreated symptomatic non-fatal PE will have a fatal recurrence
35
Q

Treatment of VTE - aims

A
  • Relieve symptoms
    • Prevent PE (DVT patients)
    • Prevent death (PE patients)
    • Prevent recurrence
    • Prevent complications - post-phlebitic syndrome (DVT), pulmonary hypertension (PE)
    • Anticoagulation is the mainstay of treatment
36
Q

Antithrombin

A
  • Genetics encode how much we produce
    • Major inhibitor of thrombin, Xa and other serine proteases in coagulation cascade e.g. Ixa
    • Heparin cofactor
      ○ Slowly inactivates thrombin in abense of heparin
      ○ More potent in presence of haperin
    • Active sites
      ○ Reactive centre - cleaved by thrombin
      ○ Heparin binding iste
    • Inherited autosomal dominant, variable clinical penetrance
      ○ One acquired defective copy of the gene is sufficient
    • Acquired causes include liver disease, warferin theraoy, protein loss (e.g. nephrotic syndrome), DIC
37
Q

heparin effect on anti-thrombin

A
  • Heparin cofactor
    ○ Slowly inactivates thrombin in abense of heparin
    More potent in presence of haperin
38
Q

antithrombin deficiency inheritance

A
  • Inherited autosomal dominant, variable clinical penetrance
    ○ One acquired defective copy of the gene is sufficient
39
Q

protein C deficiency

A
  • Vitamin K dependant protein synthesised in the liver
    • Autosomal dominant inheritance
    • Anticoagulant effect only after activation to activated protein C (aPC)
    • aPC inactivates Va and VIIIa
    • Effect markedly enhanced by protein S
    • aPC also has anti-inflammatory action, protects endothelial barrier function and enhances fibrinolysis
40
Q

Protein S deficiency

A
  • Autosomal dominant I heritance of deficiency
    • Vit K dependant
    • Co factor for protein C system
    • Acquired deficiency in pregnancy, OCP, liver disease, certain drugs, HIV infection
41
Q

Factor V leiden mutation

A
  • Point mutation in factor 5 gene
    • Arginine to glutamine at position 506
    • Protein C is unable to inactivate factor V
    • ‘activated protein C resistance’ - factor 5 is not switched off by protein C like it should be
    • Only 5% of heterozygotes for FVL will experience VTE
    • Risk factor, does not mean these people will have problems with clotting
42
Q

Prothrombin gene mutation

A
  • Prothrombin is the precursor for thrombin
    • G20210A transition in 3’ untranslated region of gene is risk factor for thrombosis
    • Heterozygous carriers have 30% higher plasma prothrombin levels
    • Mechanism: altered mRNA processing or decay rate
    • Risk factor for blood clotting, does not necessarily mean this people will have clotting issues